Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Luye Pharma Group Ltd.

www.luye.cn/lvye_en/

Latest From Luye Pharma Group Ltd.

Sun Allies With AZ To Drive China Oncology Push

India's Sun Pharma joins hands with AstraZeneca to commercialize certain 'ready to use' oncology therapies in China, hoping to capitalize on the UK firm’s strong position in this market.
China Cancer

China’s Luye Pursues Global Differentiation Strategy

Luye Pharma says it is making sound progress in developing a pipeline of added-value injectables and transdermal patches, while clinical trials for two biosimilars are also moving forward.

Value-Added Medicines Neurology

Asia Deal Watch: Takeda Licenses Curadev STING Agonist To Further Its IO Ambitions

The Japanese pharma, continuing to bolster its pipeline after buying Shire, is partnering with Skyhawk in neurodegenerative diseases under another new deal. Also, Purdue cites shifting business priorities for a decision to end Eisai collaboration on sleep disorder drug.

Deals Commercial

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

China Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • AsiaPharm Group Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • Luye Pharma Group Ltd.
  • Senior Management
  • Liu Dian-bo, Chmn. & CEO
  • Contact Info
  • Luye Pharma Group Ltd.
    Phone: (65) 21 62376350
    Bldg. 12, Shanghai Bus. Pk. III
    1036 Tianlin Rd
    Shanghai,
    Singapore
UsernamePublicRestriction

Register